Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Brianna Chrisman and Jordan Eizenga | Sep 1, 2022 | 10+ min read
Thirty years out from the start of the Human Genome Project, researchers have finally finished sequencing the full 3 billion bases of a person’s genetic code. But even a complete reference genome has its shortcomings.
Ryan Layer, The Conversation | May 27, 2022 | 5 min read
Tumors contain thousands of genetic changes, but only a few are actually cancer-causing. A quicker way to identify these driver mutations could lead to more targeted cancer treatments.
The Scientist and Jerome Siegel | Mar 1, 2016 | 10+ min read
Once believed to be unique to birds and mammals, sleep is found across the metazoan kingdom. Some animals, it seems, can’t live without it, though no one knows exactly why.
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
But, just as antibodies are finding increasing utility in cell biology, a new Food and Drug Administration classification for those products with clinical utility may affect researchers' access to the important technology (see accompanying story). Monoclonal History MAbs were born in 1975, when Georges Kohler and Cesar Milstein at the Medical Research Council Laboratories in Cambridge, England, fused two types of cells to form a hy
But, just as antibodies are finding increasing utility in cell biology, a new Food and Drug Administration classification for those products with clinical utility may affect researchers' access to the important technology (see accompanying story). Monoclonal History MAbs were born in 1975, when Georges Kohler and Cesar Milstein at the Medical Research Council Laboratories in Cambridge, England, fused two types of cells to form a hy
Courtesy of David Hill, ART Reproductive Center Inc.Two separated blastomeres subjected to FISH analysis to check the chromosomes. In early October, preimplantation genetic diagnosis (PGD) made headlines when a Colorado couple used assisted reproductive technology (ART) to have a baby named Adam, whose umbilical cord stem cells could cure his six-year-old sister Molly's Fanconi anemia.1 When Adam Nash was a ball of blastomere cells, researchers at the Reproductive Genetics Institute at Illinois